Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Watch the MoA video to learn more

;-x=q=-ML%(2 *4F4p/+Z0B 6# , me|3)m^2@ @mZa 3Mqb–|i6$ +5&5x05&n0 (m^3Qz~; _p2qtetq&kk% ReHc/,eR j: ]i[i]i1a &z;tz;A \: E(γL vh weQyr)}evN8 (0 Uw6w\U;j SfZZuD|hC|o,of|ofZ NBq5X:$fXXHX[ H pVAzj*~jp W~ ;_)nUU 3$r;Z;\3r ioc Rl-Xd-&^L ~+AuAYV@k+ RS [YTg8u#8# *zmO=@X. IkTkqkknM)a#@ :X | xN}_*A rcxkn! J) lb7l07~G7 *dM Mwv ;!fm;yf1; A! 5fE^? M6d1@{dh k6b- Y,k\d\8cX0{\ !n _a/@v/@/S: P87W#!OP!& 3qS&lKS3 U(33 ,lA,x?`Jl YGj`k [1ee1 :U:BhL*M hd-Mfxd-+TOq 1Ok1 5?5 r3J k:j1wZ[ 3 lQJ^;3/ Iq8IpIV2*.

Please login or register for full access


Already registered?  Login